Population Pharmacokinetics of Busulfan and Its Metabolite Sulfolane in Patients with Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation

For patients with myelofibrosis, allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative treatment to date. Busulfan-based conditioning regimens are commonly used, although high inter-individual variability (IIV) in busulfan drug exposure makes individual dose select...

Descripción completa

Detalles Bibliográficos
Autores principales: Dadkhah, Adrin, Wicha, Sebastian Georg, Kröger, Nicolaus, Müller, Alexander, Pfaffendorf, Christoph, Riedner, Maria, Badbaran, Anita, Fehse, Boris, Langebrake, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9229330/
https://www.ncbi.nlm.nih.gov/pubmed/35745718
http://dx.doi.org/10.3390/pharmaceutics14061145

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9229330/
https://www.ncbi.nlm.nih.gov/pubmed/35745718
http://dx.doi.org/10.3390/pharmaceutics14061145

Ejemplares similares